Aspire Biopharma Holdings (ASBP) Accumulated Expenses (2025 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Accumulated Expenses of $441614.0 for Q1 2026, up 38.41% year-over-year from $319067.0 in Q1 2025, and down 56.21% quarter-over-quarter from $1.0 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Accumulated Expenses (2025 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Accumulated Expenses for 2 consecutive years, with $441614.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 38.41% year-over-year to $441614.0; the TTM figure through Mar 2026 stood at $441614.0 (up 38.41% YoY), while the FY2025 annual figure was $1.0 million, changed N/A from the prior year.
- Accumulated Expenses slipped to $441614.0 in Q1 2026 per ASBP's latest filing, from $1.0 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $1.0 million in Q4 2025 and bottomed at $266930.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 714,088.00 |
| Mar 31, 2026 | 441,614.00 |
| Dec 31, 2025 | 1.01 Mn |
| Sep 30, 2025 | 266,930.00 |
| Jun 30, 2025 | 378,181.00 |
| Mar 31, 2025 | 319,067.00 |